Cagrilintide (Research-Grade Peptide)

Long-acting amylin analogue — for laboratory research only

Product Overview

Cagrilintide is a synthetic, long-acting analogue of the hormone amylin, engineered for sustained receptor activation.
Amylin is co-secreted with insulin and plays a role in appetite regulation, gastric emptying, and postprandial glucose
control. Cagrilintide has been investigated in preclinical and clinical research for its effects on body-weight regulation,
both as a monotherapy and in combination with GLP-1 receptor agonists. Supplied as a high-purity lyophilized powder, this
material is intended strictly for laboratory research use and not for human or veterinary administration.

Research Highlights

• Amylin Receptor Agonism: Cagrilintide activates amylin receptors involved in satiety signaling and
  energy intake regulation, supporting its investigation in obesity and metabolic research.
  Nature Medicine (2021)
• Obesity (Phase 2) Data: In a randomized Phase 2 trial in adults with overweight or obesity, cagrilintide
  demonstrated dose-dependent reductions in body weight over 26 weeks compared with placebo.
  NEJM (2021)
• Combination Research (CagriSema): Studies combining cagrilintide with semaglutide reported greater weight
  loss than either agent alone, highlighting complementary mechanisms between amylin and GLP-1 pathways.
  NEJM (2022)
• Metabolic Effects: Research has also observed favorable changes in waist circumference and metabolic
  parameters, supporting continued investigation of amylin-based therapies.
  The Lancet Diabetes & Endocrinology

Product Details & Handling

• Synonyms: Cagrilintide; AM833
• Form: Lyophilized powder, supplied in sterile vials
• Purity: ≥ 98% (Certificate of Analysis provided)
• Storage: Store at –20 °C; protect from light and moisture
• Handling: For use only in controlled laboratory environments with appropriate PPE; consult SDS for detailed safety guidance

Legal Disclaimer

This product is provided strictly for laboratory research use only.
It is not intended for human or veterinary consumption, therapeutic, diagnostic, or clinical application.
Customers are responsible for compliance with all applicable laws and institutional policies.
Cagrilintide is an investigational compound and is not approved by the FDA as a drug, supplement, or treatment.
Windy City Peptide does not provide medical advice or support related to human use.